Kestra Advisory Services LLC Has $22.90 Million Holdings in Abbott Laboratories $ABT

Key Points

• Kestra Advisory Services LLC sold 39,148 shares of Abbott Laboratories, reducing its position by 18.5%, leaving it with 172,614 shares valued at approximately $22.9 million.
• Several major institutional investors, including Vanguard and Goldman Sachs, increased their holdings in Abbott Laboratories, highlighting its strong market position.
• Abbott Laboratories recently reported quarterly earnings of $1.26 per share, aligning with analysts' expectations, and announced a quarterly dividend of $0.59 per share, reflecting a 1.8% yield.

Kestra Advisory Services LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 18.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,614 shares of the healthcare product maker's stock after selling 39,148 shares during the quarter. Kestra Advisory Services LLC's holdings in Abbott Laboratories were worth $22,897,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after purchasing an additional 2,774 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of Abbott Laboratories by 3.7% during the 4th quarter. Integrated Wealth Concepts LLC now owns 36,987 shares of the healthcare product maker's stock worth $4,184,000 after purchasing an additional 1,330 shares in the last quarter. Topsail Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $357,000. Finally, Kovitz Investment Group Partners LLC grew its stake in shares of Abbott Laboratories by 287.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 970,705 shares of the healthcare product maker's stock valued at $109,797,000 after buying an additional 720,451 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Price Performance

ABT stock traded down $0.20 during trading on Wednesday, hitting $131.39. The company had a trading volume of 4,757,752 shares, compared to its average volume of 6,771,547. The company has a market cap of $228.68 billion, a P/E ratio of 16.47, a P/E/G ratio of 2.50 and a beta of 0.70. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average price of $131.03 and a two-hundred day moving average price of $131.33. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business earned $1.14 earnings per share. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Wells Fargo & Company reduced their target price on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a report on Friday, July 18th. Finally, Mizuho increased their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $144.47.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.